Lipidem (Omega-3-Acid Triglycerides, Soya-Bean Oil Refined, Triglycerides, Medium Chain)

Omega-3-acid triglycerides are hydrolyzed after infusion to free fatty acids and glycerol, which serve as an energy source. The fatty acids are incorporated into cell‑membrane phospholipids, supporting membrane fluidity, signaling, and the synthesis of bioactive eicosanoids, thereby aiding metabolic and structural needs during parenteral nutrition.

The dose of Lipidem is individualized by the prescribing clinician based on the patient’s caloric requirements, lipid tolerance, and clinical condition. Dosage calculations consider factors such as body weight, total energy needs, and existing lipid levels, and are adjusted throughout therapy.

Safety data for Lipidem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Lipidem, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Lipidem contains a blend of omega‑3‑acid triglycerides derived from refined soy‑bean oil and medium‑chain triglycerides, offering a balanced fatty‑acid profile. Compared with traditional soybean‑oil‑only emulsions, it may provide a higher proportion of omega‑3 fatty acids, potentially influencing inflammatory pathways and lipid metabolism, though clinical choice depends on patient‑specific factors.

Lipidem must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the emulsion for discoloration or separation. Keep the product in its original container until administration to maintain sterility and stability.

Lipidem is administered intravenously as an emulsion, typically via a central venous catheter. It is infused over a prescribed period, often as part of a total parenteral nutrition regimen, and the infusion rate is adjusted according to the patient’s metabolic response and tolerance.

Serious risks include fat overload syndrome, severe hypertriglyceridaemia, allergic reactions (especially in patients with soy or egg phospholipid sensitivity), pulmonary embolism, and hepatic dysfunction. Early recognition of symptoms such as respiratory distress, marked liver enzyme elevation, or sudden drops in platelet count is essential.

Lipidem should be avoided in patients with known hypersensitivity to soy‑bean oil, egg phospholipids, or any component of the emulsion. It is also contraindicated in individuals with severe hyperlipidaemia, uncontrolled fatty‑acid metabolism disorders, or those who have experienced a previous severe reaction to lipid emulsions.